In this video, AJ Joshi, MD, Atara Biotherapeutics, San Francisco, CA, presents some data on a study which aimed to investigate the use of tabelecleucel, a targeted T-cell therapy, in patients with Epstein-Barr positive post-transplant lymphoproliferative disorder (EBV+ PTLD). Dr Joshi first gives some background information on the disease biology and current treatment options for EBV+ PTLD, drawing focus on the use of rituximab. Dr Joshi then discusses the results from this study, including the overall response rate, durability of response, and overall survival observed in patients treated with tabelecleucel. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Негізгі бет Tabelecleucel in the treatment of EBV+ PTLD
Пікірлер